CN105566329A - 一种吡唑[5,6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 - Google Patents
一种吡唑[5,6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 Download PDFInfo
- Publication number
- CN105566329A CN105566329A CN201410635578.4A CN201410635578A CN105566329A CN 105566329 A CN105566329 A CN 105566329A CN 201410635578 A CN201410635578 A CN 201410635578A CN 105566329 A CN105566329 A CN 105566329A
- Authority
- CN
- China
- Prior art keywords
- tumour
- cancer
- compound
- egfr
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410635578.4A CN105566329B (zh) | 2014-11-07 | 2014-11-07 | 一种吡唑[5,6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410635578.4A CN105566329B (zh) | 2014-11-07 | 2014-11-07 | 一种吡唑[5,6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105566329A true CN105566329A (zh) | 2016-05-11 |
CN105566329B CN105566329B (zh) | 2019-02-12 |
Family
ID=55877018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410635578.4A Active CN105566329B (zh) | 2014-11-07 | 2014-11-07 | 一种吡唑[5,6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105566329B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115141181A (zh) * | 2022-06-14 | 2022-10-04 | 温州医科大学 | 一种新型小分子化合物及其制备方法及用途 |
CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039359A2 (en) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
US20100144705A1 (en) * | 2008-12-05 | 2010-06-10 | Principia Biopharma Inc. | Egfr kinase knockdown via electrophilically enhanced inhibitors |
CN103442568A (zh) * | 2010-10-08 | 2013-12-11 | Abbvie公司 | 呋喃并[3,2-d]嘧啶化合物 |
CN103476767A (zh) * | 2011-02-09 | 2013-12-25 | 弗·哈夫曼-拉罗切有限公司 | 作为pi3激酶抑制剂的杂环化合物 |
CN103797013A (zh) * | 2011-07-21 | 2014-05-14 | 埃斯蒂维实验室股份有限公司 | 吡唑并[3,4-d]嘧啶化合物、它们的制备及作为西格玛配体的用途 |
-
2014
- 2014-11-07 CN CN201410635578.4A patent/CN105566329B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039359A2 (en) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
US20100144705A1 (en) * | 2008-12-05 | 2010-06-10 | Principia Biopharma Inc. | Egfr kinase knockdown via electrophilically enhanced inhibitors |
CN103442568A (zh) * | 2010-10-08 | 2013-12-11 | Abbvie公司 | 呋喃并[3,2-d]嘧啶化合物 |
CN103476767A (zh) * | 2011-02-09 | 2013-12-25 | 弗·哈夫曼-拉罗切有限公司 | 作为pi3激酶抑制剂的杂环化合物 |
CN103797013A (zh) * | 2011-07-21 | 2014-05-14 | 埃斯蒂维实验室股份有限公司 | 吡唑并[3,4-d]嘧啶化合物、它们的制备及作为西格玛配体的用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115141181A (zh) * | 2022-06-14 | 2022-10-04 | 温州医科大学 | 一种新型小分子化合物及其制备方法及用途 |
CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105566329B (zh) | 2019-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: in vitro and in vivo study | |
JP2021008475A (ja) | Her2増幅性癌の処置のための方法 | |
Jani et al. | PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy | |
Mohamed et al. | Medicinal attributes of pyridine scaffold as anticancer targeting agents | |
Catalano et al. | Diarylureas as antitumor agents | |
UA119971C2 (uk) | Інгібітори g12c kras | |
US20110224223A1 (en) | MTOR Modulators and Uses Thereof | |
US10774090B2 (en) | Pyrimidine compounds and pyrimido indole compounds and methods of use | |
Healy et al. | The importance of Ras in drug resistance in cancer | |
Blake et al. | Discovery of 5, 6, 7, 8-tetrahydropyrido [3, 4-d] pyrimidine inhibitors of Erk2 | |
KR20120097496A (ko) | 조합물 | |
Abd El Razik et al. | Synthesis of new pyrazolo [3, 4‐d] pyrimidine derivatives and evaluation of their anti‐inflammatory and anticancer activities | |
Dai et al. | Triazole-fused pyrimidines in target-based anticancer drug discovery | |
CN105120855A (zh) | 纤维化和癌症的治疗方法 | |
Nossier et al. | Modified pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation | |
Prasher et al. | Recent trends in rationally designed molecules as kinase inhibitors | |
CN105566329A (zh) | 一种吡唑[5,6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 | |
CN107362166B (zh) | 四氢吡啶并[4,5-]噻吩并[2,3-]嘧啶-4(3)-酮类化合物在制药中的应用 | |
Prabhu et al. | Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue | |
Kumar et al. | Epidermal growth factor receptor and its trafficking regulation by acetylation: Implication in resistance and exploring the newer therapeutic avenues in cancer | |
KR20120099219A (ko) | 조합물 | |
KR20190110581A (ko) | 암 치료 | |
Asati et al. | Recent advances in PI3 kinase inhibitors: anticancer activities and structure-activity relationships | |
JP7094879B2 (ja) | がんを処置する使用のための複素環式pdk1インヒビター | |
Theodore et al. | Design, synthesis, molecular docking and biological evaluation of novel pyrazole derivatives bearing quinoxalinone moiety as multi-targeted anticancer agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Zhiguo Inventor after: Zhang Ying Inventor after: Zhang Qiaoqiao Inventor after: Ye Qingqing Inventor after: He Fan Inventor after: Pan Kailing Inventor after: Liang Guang Inventor after: Li Xiaokun Inventor before: Zhang Ying Inventor before: Zhang Qiaoqiao Inventor before: Ye Qingqing Inventor before: He Fan Inventor before: Pan Kailing Inventor before: Liu Zhiguo Inventor before: Liang Guang Inventor before: Li Xiaokun |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210517 Address after: Room 2001, building a, Wenzhou Medical Equipment headquarters park, Xuefu North Road, Ouhai District, Wenzhou City, Zhejiang Province Patentee after: Yaogu (Wenzhou) Technology Development Co.,Ltd. Address before: Box 006, 38 Dongfang South Road, Ouhai Economic Development Zone, Wenzhou City, Zhejiang Province 325035 Patentee before: WENZHOU MEDICAL University |